Literature DB >> 33989083

Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency.

Hadis Shakeri1, Jente R A Boen1,2, Sofie De Moudt1, Jhana O Hendrickx1, Arthur J A Leloup1, Griet Jacobs1, Guido R Y De Meyer1, Gilles W De Keulenaer1,3, Pieter-Jan D F Guns1, Vincent F M Segers1,4.   

Abstract

Endothelial cells (ECs) secrete different paracrine signals that modulate the function of adjacent cells; two examples of these paracrine signals are nitric oxide (NO) and neuregulin-1 (NRG1), a cardioprotective growth factor. Currently, it is undetermined whether one paracrine factor can compensate for the loss of another. Herein, we hypothesized that NRG1 can compensate for endothelial NO synthase (eNOS) deficiency. We characterized eNOS null and wild-type (WT) mice by cardiac ultrasound and histology and we determined circulating NRG1 levels. In a separate experiment, eight groups of mice were divided into four groups of eNOS null mice and WT mice; half of the mice received angiotensin II (ANG II) to induce a more severe phenotype. Mice were randomized to daily injections with NRG1 or vehicle for 28 days. eNOS deficiency increased NRG1 plasma levels, indicating that ECs increase their NRG1 expression when NO production is deleted. eNOS deficiency also increased blood pressure, lowered heart rate, induced cardiac fibrosis, and affected diastolic function. In eNOS null mice, ANG II administration not only increased cardiac fibrosis but also induced cardiac hypertrophy and renal fibrosis. NRG1 administration prevented cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. Moreover, Nrg1 expression in the myocardium is shown to be regulated by miR-134. This study indicates that administration of endothelium-derived NRG1 can compensate for eNOS deficiency in the heart and kidneys.NEW & NOTEWORTHY ECs compensate for eNOS deficiency by increasing the secretion of NRG1. NRG1 administration prevents cardiac and renal hypertrophy and fibrosis caused by ANG II infusion and eNOS deficiency. NRG1 expression is regulated by miR-134.

Entities:  

Keywords:  NO signaling; angiotensin II; fibrosis; hypertrophy; neuregulin-1

Mesh:

Substances:

Year:  2021        PMID: 33989083     DOI: 10.1152/ajpheart.00914.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  3 in total

1.  Aortic Stiffness in L-NAME Treated C57Bl/6 Mice Displays a Shift From Early Endothelial Dysfunction to Late-Term Vascular Smooth Muscle Cell Dysfunction.

Authors:  Sofie De Moudt; Jhana O Hendrickx; Cédric Neutel; Dorien De Munck; Arthur Leloup; Guido R Y De Meyer; Wim Martinet; Paul Fransen
Journal:  Front Physiol       Date:  2022-06-16       Impact factor: 4.755

Review 2.  Neuregulin-1, a potential therapeutic target for cardiac repair.

Authors:  Yan Wang; Jianliang Wei; Peng Zhang; Xin Zhang; Yifei Wang; Wenjing Chen; Yanan Zhao; Xiangning Cui
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

3.  The chicken, the egg, and the elephant: eNOS and NRG1 in fibrosis.

Authors:  Shamama Nishat; Richard J Gumina
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-06-25       Impact factor: 5.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.